Equity Field Notes from temporal sources

[DanWebzster]

NVAX may become an EOY tax loss candidate.

raised $50mn in a 4/12/18 offering at 1.65/sh and now has > $220mn in the bank.

Lead program is their RSV vaccine. RSV has a TAM of $5B. Mothers are immunized to prevent infection of infants.

Q-1/2019 is the expected time for RSV vaccine interim analysis.

Ph1 nanoflu program addresses the problem of antigenic drift inherent in the production of currently approved flu vaccines.

The egg-based flu vaccine presently in use only protects against 30% of flu virus strains in any given season and due to antigenic drift only has ~8% efficacy. On a personal level, that makes getting vaccinated for flu a stupid decision.

The TAM for improved flu vaccine technology is $5B.

$5 2020 calls are cheap using a limit order.